Feedback
Settings

Settings

Goto Application

346,879 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 34,688
1.20250224393METHOD AND KIT FOR REDUCING INTERFERENCES IN IMMUNOASSAYS
US - 10.07.2025
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No 19011721 Applicant Siemens Healthcare Diagnostics Products GmbH Inventor Juergen PATZKE

A kit and method are described herein for detecting an analyte in a body fluid sample. The kit and method use a test-specific blocking antibody for reduction of interferences, for example as caused by heterophilic antibodies or rheumatoid factors.

2.20250222034MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLE-EXOSOMES
US - 10.07.2025
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
 Appl.No 19017125 Applicant Biotech Therapeutics, LLC Inventor John Barchilon

A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative/healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.

3.WO/2025/145815MOUSE ANTI-HUMAN MISMATCH REPAIR PROTEIN MLH1 MONOCLONAL ANTIBODY, CELL STRAIN AND USE THEREOF
WO - 10.07.2025
Int.Class C12N 5/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12Fused cells, e.g. hybridomas
16Animal cells
18Murine cells, e.g. mouse cells
20one of the fusion partners being a B lymphocyte
 Appl.No PCT/CN2024/134971 Applicant GUANGZHOU WONDFO BIOTECH CO., LTD. Inventor ZHANG, Qiankun
A monoclonal hybridoma cell strain, with the deposit number of GDMCC No. 64004. The monoclonal hybridoma cell strain can stably secrete an anti-human mismatch repair protein MLH1 monoclonal antibody, which has the advantages of good specificity and high affinity. The antibody can specifically bind to a mismatch repair protein MLH1, thereby significantly improving the specificity and sensitivity of the immunological detection of the mismatch repair protein MLH1. Particularly, the antibody can specifically recognize the MLH1 protein in tumor tissues of colon cancer, gastric cancer, breast cancer and endometrial cancer, and in a human colon cancer cell line and a human cervical cancer cell line, but does not recognize the MLH1 protein in colon cancer with MLH1 deficiency and a human colon cancer cell line with MLH1 deficiency. Therefore, the antibody can be widely applied to the preparation of various immunological detection kits.
4.20250224403DOUBLY LABELED WATER WITH ENHANCED PROTOCOL
US - 10.07.2025
Int.Class G01N 33/58
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
58involving labelled substances
 Appl.No 18408172 Applicant Calorify, Inc. Inventor Hari Mix

Doubly labeled water with enhanced protocol. One embodiment is a method including providing, to a user, a doubly labeled water (DLW) dose for the user to ingest, the DLW dose including deuterium and oxygen-18, wherein an amount of the deuterium is less than 0.12 grams per kilogram (g/kg) of body water of the user, and wherein an amount of the oxygen-18 is less than 0.18 g/kg of body water of the user. The method also includes receiving, from the user, a non-cooled shipment of urine samples collected in connection with ingestion of the DLW dose, wherein the urine samples remain uncooled after collection and during transit for a period of up to 24 days. The method further includes processing the urine samples with a liquid water isotope analyzer to determine one or more metabolic parameters of the user.

5.20250223559AXIOLOID: A STEM CELL-BASED MODEL OF HUMAN AXIAL DEVELOPMENT
US - 10.07.2025
Int.Class C12N 5/077
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
 Appl.No 18852869 Applicant KYOTO UNIVERSITY Inventor Cantas ALEV

The present disclosure relates to a pluripotent stem cell (PSC)-based method to reconstitute axial development in vitro and to a method for producing the same. The present disclosure provides a three-dimensional cellular aggregate, termed ‘axioloids’, generated in vitro from pluripotent stem and composed of mesodermal cells wherein the cellular aggregate is polarized along its antero-posterior axis and its apical-basolateral axis. This cellular aggregate can reconstitute various aspects of somitogenesis and axial development, including axial elongation, segmentation, epithelial somite formation and patterning (formation of one or more somite-like structures), and oscillation of the segmentation clock under somitogenic culture conditions. Axioloids can also be used to derive various cellular lineages and functional cell types and can be used as a platform to model and reconstitute human embryo development, disease and evolution. Axioloids can be further utilized, among other things, for the assessment of the teratogenicity and toxicology of chemical compounds, the production and testing of cellular therapy products, the study of congenital and acquired human diseases and the evaluation of ongoing and future therapeutic approaches.

6.20250223595METHOD FOR CONSTRUCTING GENE NETWORK THROUGH SINGLE-CELL TRANSCRIPTOME AND METHOD FOR DISCOVERING KEY GENE IN DIFFERENTIATION USING SAME
US - 10.07.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 18849559 Applicant KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor Kwang Hyun Cho

The present invention relates to a method for constructing a gene network through a single-cell transcriptome and a method for discovering key genes in differentiation using same, and a composition for the prevention, alleviation, or treatment of colon cancer using the target discovered through the method. The method for constructing a gene network of key genes according to the present invention employs single-cell transcriptome data and thus can be applied to all single-cell transcriptome data. The combination of MYB/HDAC2/FOXA2 discovered upon application to colon cells can serve as a cancer treatment target that promotes the differentiation of colon cancer cells to revert same into differentiated normal cells.

7.202025102754System zum Schnellnachweis von Virusinfektionen in Blutproben
DE - 10.07.2025
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No 202025102754 Applicant Abbasi Banzeer Ahsan Inventor

Ein System zum schnellen Nachweis viraler Infektionen in Blutproben, bestehend aus: ein mikrofluidisches Verarbeitungsmodul, das so konfiguriert ist, dass es eine Vollblutprobe im Mikrolitermaßstab aufnimmt und durch aufeinanderfolgende Schritte verarbeitet, darunter Plasmatrennung, Lyse viraler Partikel und Extraktion von Biomarkern; eine Biosensor-Array-Einheit, die eine Vielzahl nanostrukturierter Sensorelemente umfasst, die mit pathogenspezifischen Liganden funktionalisiert sind, wobei das Biosensor-Array in das Mikrofluidikmodul integriert ist, um eine Echtzeiterkennung viraler Nukleinsäuren oder Antigene zu ermöglichen; ein temperaturgesteuertes Amplifikationsmodul, das in den Mikrofluidkanal eingebettet ist und für die Durchführung einer isothermen Nukleinsäureamplifikation mittels Rekombinase -Polymerase-Amplifikation (RPA), Loop-vermittelter isothermer Amplifikation (LAMP) oder Helikase-abhängiger Amplifikation (HDA) konfiguriert ist; ein Signalerfassungssubsystem, das optische, elektrochemische oder piezoelektrische Wandler umfasst, die mit dem Biosensor-Array gekoppelt sind, wobei das Subsystem molekulare Interaktionsdaten in digitale Signale umwandelt; einen Prozessor für maschinelles Lernen, der operativ mit dem Signalerfassungssubsystem verbunden ist und so konfiguriert ist, dass er den Infektionsstatus mithilfe vorab trainierter Klassifizierungsmodelle mit Vertrauensbewertung und Anomaliemarkierung klassifiziert; eine drahtlose Kommunikationsschnittstelle, die operativ mit dem Prozessor für maschinelles Lernen verbunden ist, um die Ergebnisse per Fernzugriff zu verbreiten, wobei das gesamte System in einem tragbaren Gehäuse untergebracht ist, das über eine grafische Benutzeroberfläche oder einen Touchscreen bedienbar ist. embedded image

8.WO/2025/146686METHODS AND KITS FOR DETERMINING IMPAIRED NEURO-METABOLISM ASSOCIATED WITH MENTAL CONDITION AND DIETARY TREATMENT THEREOF
WO - 10.07.2025
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/IL2025/050007 Applicant HEALTHY-LONGER GMBH Inventor LEDUNGER, Joanna
The disclosure provides methods and kits, including ex vivo and computer- implemented methods, for diagnosing and classifying mental health condition, and managing thereof using neuro nutrition.
9.WO/2025/147586CONTROLLING ANTIBODY SPECIFICITIES IN A POLYCLONAL HUMORAL RESPONSE BY EPITOPE TUNING
WO - 10.07.2025
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No PCT/US2025/010205 Applicant AGILENT TECHNOLOGIES, INC. Inventor RASMUSSEN, Kim Krighaar
In alternative embodiments, provided are chimeric immunogens, and methods for making and using them, including methods for making and obtaining polyclonal antibodies specific for selected epitopes. In alternative embodiments, provided are methods for generating a balanced immune response against a plurality of epitopes present in an antigen comprising immunizing a host with a plurality of polypeptides, wherein each polypeptide comprises one or a subset of said plurality of epitopes. In alternative embodiments, provided are methods for generating a balanced, epitope-specific antibody response in a non-human mammalian host, wherein the immune response comprises generation of host antibodies specifically against (or that specifically bind to) at least one human epitope, and the method comprises administering to the host a sufficient amount of a chimeric or recombinant polypeptide to generate the epitope-specific antibody response.
10.WO/2025/147106NOVEL ORGANOID CULTURE SYSTEM FOR ASSESSING TOXICITY OF NANOMATERIALS
WO - 10.07.2025
Int.Class C12N 5/071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
 Appl.No PCT/KR2025/000057 Applicant KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE Inventor BAEK, Ah Ruem
The present invention relates to a liver organoid suspension culture method for assessing the safety and toxicity of nanomaterials and, more specifically, to a culture method in which nanomaterials can be introduced into cells constituting an organoid, wherein when a suspension culture system according to the present invention is used, the organoid culture method provides a reliable tool for assessing the stability of nanomaterials, is highly likely to be applicable to high-throughput nano safety screening, and can accelerate the research and development of nanomaterials in various fields.
# -